Now Playing
Opinion|Videos|March 5, 2024
Unraveling Type 1 Diabetes: Differences Between Type 1 and Type 2
Robert Gabbay, MD, PhD, delineates key differences between type 1 and type 2 diabetes, including autoimmune antibodies, insulin resistance, and insulin deficiency.
Advertisement
Episodes in this series
Advertisement
Related to this article
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
The study’s primary end point of event-free survival demonstrated a 49% reduction in mortality risk between the blinatumomab and control cohorts.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Imlunestrant Plus Abemaciclib for Breast Cancer
2
Higher CPAP Adherence Linked With Lower Mortality Risk in OSA
3
Lung Cancer Progress Drives Down US Cancer Death Rates
4
FDA Approves First Treatment for Sanfilippo Syndrome Type A
5